Botox continues to be AGN’s main profitability engine, and this probably won’t change anytime soon. 2Q16 worldwide Botox sales were $720M, +14% YoY and +13% QoQ. (The high QoQ growth is due, in part, to the seasonality of cosmetic treatments.) http://finance.yahoo.com/news/allergan-reports-strong-second-quarter-110000207.html